42,000 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired a new stake in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) during the fourth quarter, Holdings Channel.com reports. The firm acquired 42,000 shares of the company’s stock, valued at approximately $520,000.

A number of other hedge funds have also bought and sold shares of the company. Handelsbanken Fonder AB bought a new position in Wave Life Sciences during the fourth quarter valued at $628,000. New York State Common Retirement Fund increased its position in Wave Life Sciences by 6.8% during the fourth quarter. New York State Common Retirement Fund now owns 109,084 shares of the company’s stock valued at $1,349,000 after acquiring an additional 6,900 shares during the last quarter. Principal Financial Group Inc. bought a new position in Wave Life Sciences during the fourth quarter valued at $3,076,000. Rhumbline Advisers increased its position in Wave Life Sciences by 16.1% during the fourth quarter. Rhumbline Advisers now owns 124,840 shares of the company’s stock valued at $1,544,000 after acquiring an additional 17,316 shares during the last quarter. Finally, James J. Burns & Company LLC increased its position in Wave Life Sciences by 11.0% during the fourth quarter. James J. Burns & Company LLC now owns 111,111 shares of the company’s stock valued at $1,374,000 after acquiring an additional 11,000 shares during the last quarter. Institutional investors own 89.73% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. StockNews.com lowered shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 13th. Truist Financial boosted their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Mizuho boosted their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, November 13th. Finally, B. Riley boosted their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.22.

Insider Buying and Selling

In other Wave Life Sciences news, CEO Paul Bolno sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the sale, the chief executive officer now directly owns 217,351 shares of the company’s stock, valued at approximately $3,260,265. This represents a 18.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 29.10% of the stock is owned by insiders.

Wave Life Sciences Stock Up 2.9 %

NASDAQ:WVE opened at $11.33 on Friday. Wave Life Sciences Ltd. has a 1-year low of $3.95 and a 1-year high of $16.74. The company has a 50-day moving average of $12.09 and a 200 day moving average of $10.84.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.